Table 1.
Baseline characteristics by baseline MRA use
| Characteristic | Dapagliflozin |
Placebo |
||
|---|---|---|---|---|
| MRA use (n = 109) | No MRA use (n = 2043) | MRA use (n = 120) | No MRA use (n = 2032) | |
| Age, yr | 61.8 ± 10.6 | 61.8 ± 12.1 | 62.6 ± 10.7 | 61.8 ± 12.2 |
| Female sex, n (%) | 30 (27.5) | 679 (33.2) | 32 (26.7) | 684 (33.7) |
| BMI, kg/m2 | 32.2 ± 7.9 | 29.2 ± 5.9 | 33.1 ± 7.3 | 29.4 ± 6.2 |
| Blood pressure, mm Hg | ||||
| Systolic | 138.1 ± 19.2 | 136.7 ± 17.4 | 137.9 ± 19.7 | 137.4 ± 17.2 |
| Diastolic | 76.5 ± 12.1 | 77.5 ± 10.6 | 77.6 ± 10.8 | 77.5 ± 10.3 |
| eGFR, ml/min per 1.73 m2 | 44.3 ± 12.4 | 43.2 ± 12.3 | 43.1 ± 11.4 | 43.0 ± 12.5 |
| Median UACR, mg/g [IQR] | 1165 [541–1977] | 951 [469–1894] | 1005 [477–2010] | 931 [484–1861] |
| HbA1c, % | 7.1 ± 1.5 | 7.1 ± 1.7 | 7.4 ± 1.9 | 7.0 ± 1.7 |
| Type 2 diabetes, n (%) | 82 (75.2) | 1373 (67.2) | 89 (74.2) | 1362 (67.0) |
| Heart failure history, n (%) | 36 (33.0) | 199 (9.7) | 45 (37.5) | 188 (9.3) |
| Baseline medication use, n (%) | ||||
| MRAa | ||||
| Spironolactone | 90 (82.6) | 0 (0) | 106 (88.3) | 0 (0) |
| Eplerenone | 18 (16.5) | 0 (0) | 14 (11.7) | 0 (0) |
| Loop diuretic | 62 (56.9) | 461 (22.6) | 67 (55.8) | 466 (22.9) |
| Thiazide diuretic | 36 (33.0) | 416 (20.4) | 28 (23.3) | 426 (21.0) |
| β-blocker | 73 (67.0) | 773 (37.8) | 82 (68.3) | 752 (37.0) |
| Statin | 87 (79.8) | 1308 (64.0) | 93 (77.5) | 1306 (64.3) |
| Antithrombotic agent | 70 (64.2) | 952 (46.6) | 87 (72.5) | 933 (45.9) |
BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; IQR, interquartile range; MRA, mineralocorticoid receptor antagonist; UACR, urinary albumin-to-creatinine ratio.
Data are presented as mean ± SD unless otherwise stated.
a
One patient in the dapagliflozin group was treated with an MRA, but the type of MRA (spironolactone or eplerenone) was unknown.